Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from SciSparc Ltd. ( (SPRC) ) is now available.
On October 24, 2025, SciSparc Ltd. announced the completion of its acquisition of Neurothera Labs Inc., a publicly traded company on the TSX Venture Exchange. Through this transaction, SciSparc transferred its advanced clinical stage pharmaceutical portfolio and gained a controlling interest in Neurothera. The acquisition, valued at approximately CAD 4.5 million, positions SciSparc to expand its presence in the pharmaceutical and supplemental sectors. This strategic move is expected to enhance SciSparc’s industry positioning and potentially increase its influence in the market.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases. The company, alongside its subsidiary Neurothera Labs Inc., is engaged in drug development programs utilizing cannabinoid pharmaceuticals, including treatments for Tourette syndrome, Alzheimer’s disease, autism spectrum disorder, and status epilepticus.
Average Trading Volume: 4,715,393
Technical Sentiment Signal: Sell
Current Market Cap: $6.52M
For a thorough assessment of SPRC stock, go to TipRanks’ Stock Analysis page.